In the presence of GPR43 or GPR109A, treatment with acetate, butyrate, or propionate protected diabetic mice from nephropathy and inhibited high glucose-induced inflammation in renal tubular cells and podocytes. This evidence concerns the gene FFAR2 and kidney disorder.